More Bang for the Buck? DESCRIPA Thrifty in Biomarker Studies
Among global initiatives aimed at understanding how biomarkers elucidate the progression of Alzheimer’s disease, DESCRIPA appears to do much with little...
463 RESULTS
Sort By:
Among global initiatives aimed at understanding how biomarkers elucidate the progression of Alzheimer’s disease, DESCRIPA appears to do much with little...
Scientists worldwide now perform amyloid imaging on scores of research participants to figure out how Aβ buildup relates to other markers of neurodegeneration...
Like a blue moon, could oligomeric amyloid-β in the cerebrospinal fluid (CSF) be too rare to be informative?...
Clifford Jack's hypothetical model showing biomarkers emerging at different stages of AD surged to the top of the Most-Popular-Slide-at-Conferences chart...
In a snowy mountain town in Austria, 75 scientists traded data and discussion of AD treatment approaches...
The quest for health insurance coverage of brain amyloid scanning just took a twist...
Merck’s BACE inhibitor development program began enrolling last month for an 18-month Phase 2/3 trial of its lead compound (MK-8931) in mild to moderate AD...
With growing recognition that AD kicks off years before cognitive symptoms appear, scientists have ramped up efforts to understand early biomarker changes...
Merck announced this week that it has begun enrolling for the largest clinical trial of a β-secretase (BACE1) inhibitor in Alzheimer’s disease patients...
Data miners: Start your search engines...
When a new disease emerges, clinicians grapple early on with how to diagnose it...
What exactly goes on in the brains of people when blows to the head turn into a degenerative tau disease months or even years after the trauma...
Professional boxing offers a unique opportunity to study the natural history of CTE for an understanding of its presymptomatic pathogenesis and progression...
As neuroimaging advances paint ever more detailed pictures of the brain’s wear and tear during Alzheimer’s disease, a glaring problem emerges...
The 5th Clinical Trials in Alzheimer’s Disease conference showcased the field’s pressing need for biomarkers as outcome measures...